Characteristics of patients before avelumab treatment
| Characteristics . | Total, n (%) . | Responders, n (%) . | Nonresponders, n (%) . | P* . |
|---|---|---|---|---|
| Age (y) | ||||
| ≤60 | 16 (76) | 8 (100) | 8 (62) | .111 |
| >60 | 5 (24) | 0 | 5 (48) | |
| Sex | ||||
| Male | 13 (62) | 6 (75) | 7 (54) | .400 |
| Female | 8 (38) | 2 (25) | 6 (46) | |
| Performance status | ||||
| ECOG 0/1 | 20 (95) | 8 (100) | 12 (92) | >.999 |
| ECOG ≥2 | 1 (5) | 0 | 1 (8) | |
| Serum LDH | ||||
| Normal | 5 (24) | 2 (25) | 3 (23) | >.999 |
| Increased | 16 (76) | 6 (75) | 10 (77) | |
| Stage | ||||
| I/II | 2/2 (19) | 2 (25) | 2 (15) | .862 |
| III/IV | 0/17 (81) | 6 (75) | 11 (85) | |
| Bone marrow involvement | ||||
| Absence | 14 (67) | 5 (63) | 9 (69) | >.999 |
| Presence | 7 (33) | 3 (37) | 4 (31) | |
| Disease status | ||||
| Relapsed | 8 (38) | 2 (25) | 6 (46) | .400 |
| Refractory | 13 (62) | 6 (75) | 7 (54) | |
| EBV DNA in blood | ||||
| Nondetectable | 4 (19) | 0 | 4 (31) | .131 |
| Detectable | 17 (81) | 8 (100) | 9 (69) | |
| PINK-E risk | ||||
| Low | 4 (19) | 2 (25) | 2 (15) | .563 |
| Intermediate | 6 (29) | 3 (38) | 3 (23) | |
| High | 11 (52) | 3 (38) | 8 (62) | |
| Immune subtype | ||||
| Immune tolerance | 1 (5) | 1 (13) | 0 | .007 |
| Immune evasion A | 10 (48) | 7 (88) | 3 (23) | |
| Immune evasion B | 5 (24) | 0 | 5 (39) | |
| Immune silenced | 5 (24) | 0 | 5 (39) | |
| Number of previous treatments | ||||
| <2 | 7 (33) | 3 (38) | 4 (31) | >.999 |
| ≥2 | 14 (67) | 5 (62) | 9 (69) | |
| Autologous SCT | ||||
| Not done | 16 (76) | 6 (75) | 10 (77) | >.999 |
| Done | 5 (24) | 2 (25) | 3 (23) |
| Characteristics . | Total, n (%) . | Responders, n (%) . | Nonresponders, n (%) . | P* . |
|---|---|---|---|---|
| Age (y) | ||||
| ≤60 | 16 (76) | 8 (100) | 8 (62) | .111 |
| >60 | 5 (24) | 0 | 5 (48) | |
| Sex | ||||
| Male | 13 (62) | 6 (75) | 7 (54) | .400 |
| Female | 8 (38) | 2 (25) | 6 (46) | |
| Performance status | ||||
| ECOG 0/1 | 20 (95) | 8 (100) | 12 (92) | >.999 |
| ECOG ≥2 | 1 (5) | 0 | 1 (8) | |
| Serum LDH | ||||
| Normal | 5 (24) | 2 (25) | 3 (23) | >.999 |
| Increased | 16 (76) | 6 (75) | 10 (77) | |
| Stage | ||||
| I/II | 2/2 (19) | 2 (25) | 2 (15) | .862 |
| III/IV | 0/17 (81) | 6 (75) | 11 (85) | |
| Bone marrow involvement | ||||
| Absence | 14 (67) | 5 (63) | 9 (69) | >.999 |
| Presence | 7 (33) | 3 (37) | 4 (31) | |
| Disease status | ||||
| Relapsed | 8 (38) | 2 (25) | 6 (46) | .400 |
| Refractory | 13 (62) | 6 (75) | 7 (54) | |
| EBV DNA in blood | ||||
| Nondetectable | 4 (19) | 0 | 4 (31) | .131 |
| Detectable | 17 (81) | 8 (100) | 9 (69) | |
| PINK-E risk | ||||
| Low | 4 (19) | 2 (25) | 2 (15) | .563 |
| Intermediate | 6 (29) | 3 (38) | 3 (23) | |
| High | 11 (52) | 3 (38) | 8 (62) | |
| Immune subtype | ||||
| Immune tolerance | 1 (5) | 1 (13) | 0 | .007 |
| Immune evasion A | 10 (48) | 7 (88) | 3 (23) | |
| Immune evasion B | 5 (24) | 0 | 5 (39) | |
| Immune silenced | 5 (24) | 0 | 5 (39) | |
| Number of previous treatments | ||||
| <2 | 7 (33) | 3 (38) | 4 (31) | >.999 |
| ≥2 | 14 (67) | 5 (62) | 9 (69) | |
| Autologous SCT | ||||
| Not done | 16 (76) | 6 (75) | 10 (77) | >.999 |
| Done | 5 (24) | 2 (25) | 3 (23) |
LDH, lactate dehydrogenase
χ2 test for responders and nonresponders.